［1］Metzger M J，et al．Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams［J］．Cell，2015，161（2）：255-263.
［2］Zhou C．Lung cancer molecular epidemiology in China：recent trends［J］．Transl Lung Cancer Res．2014，3（5）：270-279.
［3］Yock T I，et al．Quality of life outcomes in proton and photon treated pediatric brain tumor survivors［J］．Radiother Oncol，2014，113（1）：89-94.
［4］Yadav M，et al．Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing［J］．Nature，2014，515（7528）：572-576.
［5］Warren G W，et al．The 2014 Surgeon General's report：“The health consequences of smoking — 50 years of progress”：a paradigm shift in cancer care［J］．Cancer，2014，120（13）：1914-1916.
［6］Solomon B J，et al．First-line crizotinib versus chemotherapy in ALK-positive lung cancer［J］．N Engl J Med，2014，371（23）：2167-2177.
［7］Snyder A，et al．Genetic basis for clinical response to CTLA-4 blockade in melanoma［J］．N Engl J Med，2014，371（23）：2189-2199.
［8］Shi Y，et al．A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology （PIONEER） ［J］．J Thorac Oncol，2014，9（2）：154-162.
［9］Shen L，Ji H F．Ceritinib in ALK-rearranged non-small-cell lung cancer［J］．N Engl J Med，2014，370（26）：2537.
［10］Shaw A T，Engelman J A．Ceritinib in ALK-rearranged non-small-cell lung cancer［J］．N Engl J Med，2014，370（26）：2537-2539.
［11］Sayin V I，et al．Antioxidants accelerate lung cancer progression in mice［J］．Sci Transl Med，2014，6（221）：221ra15.
［12］Mitin T A，Zietman L．Promise and pitfalls of heavy-particle therapy［J］．J Clin Oncol，2014，32（26）：2855-2863.
［13］Mendenhall N P，et al．Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer［J］．Int J Radiat Oncol Biol Phys，2014，88（3）：596-602.
［14］Maude S L，et al．Chimeric antigen receptor T cells for sustained remissions in leukemia［J］．N Engl J Med，2014，371（16）：1507-1517.
［15］Lin Y，et al．Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers［J］．Proc Natl Acad Sci U S A，2014，111（42）：E4504-4512.
［16］Herbst R S，et al．Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients［J］．Nature，2014，515（7528）：563-567.
［17］Gubin M M，et al．Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens［J］．Nature，2014，515（7528）：577-581.
［18］Gragert L，et al．HLA match likelihoods for hematopoietic stem-cell grafts in the U．S．registry［J］．N Engl J Med，2014，371（4）：339-348.
［19］Brastianos K，et al．Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas［J］．Nat Genet，2014，46（2）：161-165.
［20］Bonadies D C，et al．Adverse events in cancer genetic testing：the third case series［J］．Cancer J，2014，20（4）：246-53.
［21］Retraction notice to“Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize”Food Chem Toxicol，2014，63：244.
［22］Wolchok J D，et al．Nivolumab plus ipilimumab in advanced melanoma［J］．N Engl J Med，2013，369（2）：122-133.
［23］Watson I R，et al．Emerging patterns of somatic mutations in cancer［J］．Nat Rev Genet，2013，14（10）：703-718.
［24］Vacchelli E，et al．Trial watch：Oncolytic viruses for cancer therapy［J］．Oncoimmunology，2013，2（6）：e24612.
［25］Shi Y，et al．Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer （ICOGEN）：a randomised，double-blind phase 3 non-inferiority trial［J］．Lancet Oncol，2013，14（10）：953-961.
［26］Nixon I J，et al．The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer，based on Memorial Sloan-Kettering Cancer Center risk group stratification［J］．Thyroid，2013，23（6）：683-694.
［27］Li Y，et al．Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer［J］．PLoS One，2013，8（1）：e52093.
［28］Lawrence M S，et al．Mutational heterogeneity in cancer and the search for new cancer-associated genes［J］．Nature，2013，499（7457）：214-218.
［29］Hamid O，et al．Safety and tumor responses with lambrolizumab （anti-PD-1） in melanoma［J］．N Engl J Med，2013，369（2）：134-144.
［30］Chung C S，et al．Incidence of second malignancies among patients treated with proton versus photon radiation［J］．Int J Radiat Oncol Biol Phys，2013，87（1）：46-52.
［31］Arcila M E，et al．EGFR exon 20 insertion mutations in lung adenocarcinomas：prevalence，molecular heterogeneity，and clinicopathologic characteristics［J］．Mol Cancer Ther，2013，12（2）：220-229.
［32］Wang Y C，et al．Comparison of Cancer Incidence between China and the USA［J］．Cancer Biol Med，2012，9（2）：128-132.
［33］Topalian S L，et al．Safety，activity，and immune correlates of anti-PD-1 antibody in cancer［J］．N Engl J Med，2012，366（26）：2443-2454.
［34］Seralini G E，et al．Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize［J］．Food Chem Toxicol，2012，50（11）：4221-4231.
［35］Lim S S，et al．A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions，1990-2010：a systematic analysis for the Global Burden of Disease Study 2010［J］．Lancet，2012，380（9859）：2224-2260.
［36］Govindan R，et al．Genomic landscape of non-small cell lung cancer in smokers and never-smokers［J］．Cell，2012，150（6）：1121-1134.
［37］An S J，et al．Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status［J］．PLoS One，2012，7（6）：e40109.
［38］Zava T T，Zava D T．Assessment of Japanese iodine intake based on seaweed consumption in Japan：A literature-based analysis［J］．Thyroid Res，2011，4：14.
［39］Wagle N，et al．Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling［J］．J Clin Oncol，2011，29（22）：3085-3096.
［40］Sequist L V，et al．Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］．Sci Transl Med，2011，3（75）：75ra26.
［41］Ramaekers B L，et al．Systematic review and meta-analysis of radiotherapy in various head and neck cancers：comparing photons，carbon-ions and protons［J］．Cancer Treat Rev，2011，37（3）：185-201.
［42］Pederson T，Mukherjee S．The Emperor of All Maladies A Biography of Cancer［J］．Science，2011，332（6028）：423-423.
［43］Moeller B J，et al．Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy［J］．Radiat Oncol，2011，6：58.
［44］Miller L H，Su X．Artemisinin：discovery from the Chinese herbal garden［J］．Cell，2011，146（6）：855-858.
［45］Kantoff W，et al．Sipuleucel-T immunotherapy for castration-resistant prostate cancer［J］．N Engl J Med，2010，363（5）：411-422.
［46］Domchek S M，et al．Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality［J］．JAMA，2010，304（9）：967-975.
［47］Sawka A M，et al．Second primary malignancy risk after radioactive iodine treatment for thyroid cancer：a systematic review and meta-analysis［J］．Thyroid，2009，19（5）：451-457.
［48］Little M P．Cancer and non-cancer effects in Japanese atomic bomb survivors［J］．J Radiol Prot，2009，29（2A）：A43-59.
［49］Lawenda B D，et al．Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy？［J］．J Natl Cancer Inst，2008，100（11）：773-783.
［50］Dishop M K，Kuruvilla S．Primary and metastatic lung tumors in the pediatric population：a review and 25-year experience at a large children's hospital［J］．Arch Pathol Lab Med，2008，132（7）：1079-1103.
［51］Ballen K K，et al．Collection and preservation of cord blood for personal use［J］．Biol Blood Marrow Transplant，2008，14（3）：356-363.
［52］Schoder H，Gonen M．Screening for cancer with PET and PET/CT：potential and limitations［J］．J Nucl Med，2007，48 Suppl 1：4S-18S.
［53］McLaughlin J R，et al．Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations：a case-control study［J］．Lancet Oncol，2007，8（1）：26-34.
［54］Kelly E，Russell S J．History of oncolytic viruses：genesis to genetic engineering［J］．Mol Ther，2007，15（4）：651-659.
［55］Eapen M，et al．Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia：a comparison study［J］．Lancet，2007，369（9577）：1947-1954.
［56］Bjelakovic G，et al．Mortality in randomized trials of antioxidant supplements for primary and secondary prevention：systematic review and meta-analysis［J］．JAMA，2007，297（8）：842-857.
［57］Pearse A M，Swift K．Allograft theory：transmission of devil facial-tumour disease［J］．Nature，2006，439（7076）：549.
［58］Murgia C，et al．Clonal origin and evolution of a transmissible cancer［J］．Cell，2006，126（3）：477-487.
［59］Garber K．China approves world's first oncolytic virus therapy for cancer treatment［J］．J Natl Cancer Inst，2006，98（5）：298-300.
［60］Druker B J，et al．Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia［J］．N Engl J Med，2006，355（23）：2408-2417.
［61］Lundkvist J，et al．Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma［J］．Cancer，2005，103（4）：793-801.
［62］Ludwig J A，Weinstein J N．Biomarkers in cancer staging，prognosis and treatment selection［J］．Nat Rev Cancer，2005，5（11）：845-856.
［63］van der Zee，J．Heating the patient：a promising approach？［J］．Ann Oncol，2002，13（8）：1173-1184.
［64］Srivastava S R．Gopal-Srivastava，Biomarkers in cancer screening：a public health perspective［J］．J Nutr，2002，132（8 Suppl）：2471S-2475S.
［65］Miralbell R，et al．Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors［J］．Int J Radiat Oncol Biol Phys，2002，54（3）：824-829.
［66］Nishimura H，et al．Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor［J］．Immunity，1999，11（2）：141-151.
［67］Patterson R E，et al．Vitamin supplements and cancer risk：the epidemiologic evidence［J］．Cancer Causes Control，1997，8（5）：786-802.
［68］Jha P，et al．The antioxidant vitamins and cardiovascular disease．A critical review of epidemiologic and clinical trial data［J］．Ann Intern Med，1995，123（11）：860-872.
［69］Ferrara J L，Abhyankar S，Gilliland D G.Cytokine storm of graft-versus-host disease：a critical effector role for interleukin-1［J］．Transplant Proc，1993，25（1 Pt 2）：1216-1217.
［70］Newcomb P A，Carbone P P．The health consequences of smoking．Cance［J］r．Med Clin North Am，1992，76（2）：305-331.
［71］Martuza R L，et al．Experimental therapy of human glioma by means of a genetically engineered virus mutant［J］．Science，1991，252（5007）：854-856.
［72］Rosenberg S A，et al．Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer［J］．N Engl J Med，1985，313（23）：1485-1492.
［73］Morahan P S，et al．Paradoxical effects of immunopotentiators on tumors and tumor viruses［J］．J Infect Dis，1976，133 Suppl：A249-255.
［74］Yohn D S，et al.Oncolytic potentials of nonhuman viruses for human cancer．Ⅱ．Effects of five viruses on heterotransplantable human tumors［J］．J Natl Cancer Inst，1968，41（2）：523-529.
［75］Moore A E．Effects of viruses on tumors［J］．Annu Rev Microbiol，1954，8：393-410.
［76］Southam C M，Moore A E．Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus［J］．Cancer，1952，5（5）：1025-1034.
［77］CBSnews .Killing Cancer［OL］．http://www.cbsnews.com/news/polio-cancer-treatment-duke-university-60-minutes-scott-pelley/2015，3.29.
［78］https://clinicaltrials.gov/ct2/show/NCT0149189
［79］Li Z，et.al，Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells［J］．Cancer Cell．2009，2；15（6）：501-513.
［80］Gromeier M．et.al，Oncolytic polio virotherapy of cancer.Cancer［J］．2014，120（21）：3277-3286.